Nextgen Biomed Ltd (NXGN)
Nov 10, 2023 - NXGN was delisted (reason: acquired by Thoma Bravo)
23.94
+0.03 (0.13%)
Inactive · Last trade price on Nov 8, 2023
Company Description
Nextgen Biomed Ltd develops topical treatment for psoriasis.
The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010.
Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.
Nextgen Biomed Ltd
| Country | Israel |
| Founded | 1990 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Harel Hershtik |
Contact Details
Address: 132 Azrieli Towers Round Building Tel Aviv, California 6701101 Israel | |
| Phone | 972 9 950 0555 |
| Website | nextgen-biomed.com |
Stock Details
| Ticker Symbol | NXGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | ILS |
| CIK Code | 0000708818 |
| CUSIP Number | 65343C102 |
| ISIN Number | US65343C1027 |
| Employer ID | 95-2888568 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| David William Sides | Chief Executive Officer, President and Director |
| James Robert Arnold Jr. | Executive Vice President and Chief Financial Officer |
| David A. Metcalfe | Executive Vice President and Chief Technology Officer |
| Mitchell L. Waters | Executive Vice President of Commercial Growth |
| Srinivas S. Velamoor | Executive Vice President, Chief Growth and Strategy Officer |
| David Ahmadzai | Senior Vice President, Corporate Controller and Chief Accounting Officer |
| David Slazyk | Chief Information and Security Officer |
| Matthew Scalo | Vice President of Investor Relations |
| Jeffrey D. Linton | Executive Vice President, General Counsel and Secretary |
| Colleen Edwards | Senior Vice President of Marketing |